{"id":196455,"date":"2026-08-13T20:31:04","date_gmt":"2026-08-13T12:31:04","guid":{"rendered":"https:\/\/www.chinamoneynetwork.com\/?p=159670"},"modified":"2026-08-13T20:31:04","modified_gmt":"2026-08-13T12:31:04","slug":"innovative-drug-yivoksizumab-trade-name-yidafang-approved-for-new-indication-in-first-line-treatment-of-advanced-squamous-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2026\/08\/13\/innovative-drug-yivoksizumab-trade-name-yidafang-approved-for-new-indication-in-first-line-treatment-of-advanced-squamous-cell-lung-cancer\/","title":{"rendered":"Innovative Drug Yivoksizumab (trade name: Yidafang\u00ae) Approved for New Indication in First-Line Treatment of Advanced Squamous Cell Lung Cancer"},"content":{"rendered":"Kangfang Biotech's innovative drug Yivoksizumab (trade name: Yidafang\u00ae) has been approved by the National Medical Products Administration for a new...","protected":false},"excerpt":{"rendered":"<p>Kangfang Biotech's innovative drug Yivoksizumab (trade name: Yidafang\u00ae) has been approved by the National Medical Products Administration for a new&#8230;<\/p>\n","protected":false},"author":252,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[325,288,194,494,401,1542,334],"tags":[2210,7582,8753,5256,10733,13710,13711,13712,13713],"class_list":["post-196455","post","type-post","status-publish","format-standard","hentry","category-education","category-medicine","category-news-chinese-law","category-pharmaceutical","category-shanghai","category-technology","category-university","tag-america","tag-biotech","tag-cancer-treatment","tag-healthcare","tag-industry","tag-kangfang-biotech","tag-lung-cancer","tag-nsclc","tag-yivoksizumab"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/252"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=196455"}],"version-history":[{"count":1,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196455\/revisions"}],"predecessor-version":[{"id":196456,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196455\/revisions\/196456"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=196455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=196455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=196455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}